Dalteparin sodium
Template:Short description Template:Cs1 configTemplate:Short description Page Template:Infobox drug/styles.css has no content.
Page Module:Infobox/styles.css has no content.
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism and to reduce the risk of a stroke or heart attack.[2] Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin.[3] It is normally administered by self-injection.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism (VTE), dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events.[4] Dalteparin is not superior to unfractionated heparin in preventing blood clots.[5]
Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.[6] Approximately 70% of dalteparin is excreted through kidneys based on animal studies.[7]
In May 2019, the U.S. Food and Drug Administration (FDA) approved Fragmin injection to reduce the recurrence of symptomatic VTE in pediatric patients one month of age and older.[8] It is on the World Health Organization's List of Essential Medicines.[9]
References
Page Template:Reflist/styles.css has no content.
- ^ a b Page Module:Citation/CS1/styles.css has no content."Dalteparin (Fragmin) Use During Pregnancy". Drugs.com. 27 November 2019. Retrieved 1 June 2020.
- ^ Dalteparin - Subcutaneous Injection, HealthLinkBC | https://www.healthlinkbc.ca/medications/fdb0271 Script error: No such module "webarchive".
- ^ Pfizer Medical Information: Fragmin Pharmacodynamics | https://www.pfizermedicalinformation.ca/en-ca/fragmin/action-and-clinical-pharmacology# Script error: No such module "webarchive".
- ^ Page Module:Citation/CS1/styles.css has no content.Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a Coumadin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med. 349 (2): 146–53. doi:10.1056/NEJMoa025313. PMID 12853587.
- ^ Page Module:Citation/CS1/styles.css has no content.The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group (2011). "Dalteparin versus unfractionated heparin in critically ill patients". New England Journal of Medicine. 364 (14): 1305–1314. doi:10.1056/NEJMoa1014475. PMID 21417952.
- ^ Page Module:Citation/CS1/styles.css has no content.Douketis J, Cook D, Meade M, et al. (2008). "Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin". Arch Intern Med. 168 (16): 1805–1812. doi:10.1001/archinte.168.16.1805. PMID 18779469. S2CID 1513885.
- ^ Pfizer Medication Information: Fragmin Pharmacokinetics | https://www.pfizermedicalinformation.ca/en-ca/fragmin/action-and-clinical-pharmacology# Script error: No such module "webarchive".
- ^ Page Module:Citation/CS1/styles.css has no content."FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots, PM FDA, May 16, 2019". U.S. Food and Drug Administration (FDA). Archived from the original on September 14, 2019. Retrieved 17 May 2019.
- ^ Page Module:Citation/CS1/styles.css has no content.World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
External links
- Page Module:Citation/CS1/styles.css has no content."Dalteparin sodium". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on July 2, 2020.
Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
